Business

Alzheimer’s drug Leqembi promises to give patients more time, but they face a long road to treatment

Leqembi’s rollout has been slowed by bottlenecks related to reimbursement uncertainties, diagnostic test requirements and regular brain scans, among others.

Previous post Nelson Peltz steps down as chair of Wendy’s board, starting a new era for burger chain
Next post Stick to defensive stocks as short-term yields dive, say JPMorgan strategists

More Stories